EDITORIAL
About CJC-1295 Prescribed
What this site is. What it is not. Why the 'prescribed' modifier in the domain reads as specification, not authorization.
What this site is
CJC-1295 Prescribed is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. The site organizes the indexed phase-1 record — primarily Teichman 2006 and follow-on pharmacokinetic, proteomic, and preclinical work — alongside the regulatory file (the FDA 2023 503A Pharmacy Compounding Advisory Committee briefing) and the WADA Prohibited List entry, and presents the record as a feature-by-feature platform overview. We are not a clinic. We do not employ clinicians. We do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
On the domain name
The 'prescribed' modifier in cjc1295prescribed.com is intended in its older sense — set out as a specification — rather than its commercial sense of authorization for use. CJC-1295 is not FDA-approved for any indication, and this site does not describe a prescribing relationship, recommend a course of treatment, or refer readers to clinicians who would. The modifier is editorial framing — a position the publisher occupies relative to the literature. What is prescribed here is the structure of the overview: thirty residues, four substitutions, one optional linker, a half-life that runs in days or in minutes depending on which variant the literature is discussing. The site reads as a specification sheet for the research record, not as a recommendation.
Editorial method
Every quantitative claim on every page traces back to a numbered citation in the references index. Phase-1 dose ranges, half-life figures, IGF-1 fold-change values, proteomic shifts, and the regulatory timeline are each anchored to a specific published paper, FDA document, or WADA entry. Where the indexed literature is silent — long-term human safety, fertility data, hair-related endpoints — the site says so explicitly rather than implying coverage by omission. The platform-overview register (feature cards, comparison tables, spec chips) is a presentational choice; it is not a claim that the compound is itself an approved platform or product.
What this site is not
Not a clinic. Not a pharmacy. Not a vendor. Not a prescriber. We do not provide medical advice and we do not facilitate access to CJC-1295. We do not have a clinical team, doctors on staff, or pharmacists. The compound is not FDA-approved for any indication and is prohibited under the WADA Code at all times in and out of competition for athletes subject to that code.